

## antiviral and associated therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
favipiravir	6 studies <sup>1</sup>	-	1.25 [0.21 ; 7.62], 1 RCT, I2=0% inconclusive result	1.12 [0.02 ; 62.74], 1 RCT, I2=0% inconclusive result	0.98 [0.21 ; 4.57], 2 RCTs, I2=32% inconclusive result
chloroquine and derivatives	3 studies <sup>2</sup>	-	-	0.66 [0.04 ; 11.04], 2 RCTs, I2=0% inconclusive result	16.33 [2.80 ; 95.27], 1 study, I2=0% certainty unassessable
remdesivir	2 studies <sup>3</sup>	-	1.29 [1.12 ; 1.49], 1 RCT, I2=0% certainty unassessable	0.55 [0.36 ; 0.84], 1 RCT, I2=0% certainty unassessable	-
darunavir cobicistat	1 study <sup>4</sup>	2.07 [0.06 ; 66.79], 1 RCT, I2=0% inconclusive result	-	1.00 [0.02 ; 53.89], 1 RCT, I2=0% inconclusive result	0.82 [0.36 ; 1.87], 1 RCT, I2=0% inconclusive result
hydroxychloroquine plus macrolides	1 study <sup>5</sup>	-	-	1.14 [0.56 ; 2.32], 1 study, I2=0% inconclusive result	-
nirmatrelvir / ritonavir (Paxlovid)	1 study <sup>6</sup>	-	-	-	-
umifenovir (arbidol)	1 study <sup>7</sup>	-	-	-	-

## Notes

<sup>1</sup>Chang Chen et al., 2020 (ChiCTR2000030254) ; jRCTs041190120, 2020 (jRCTs041190120) ; Lou (FAVIPIRAVIR), 2020 (ChiCTR2000029544) ; NCT04310228-FAVI (Zhao), 2020 (ChiCTR2000030894) ; Calik, 2020 () ; Cai -FAVIPIRAVIR, 2020 (ChiCTR2000029600)

<sup>2</sup>Chen, ChiCTR2000030054 - Chloroquine, 2020 (ChiCTR2000030054) ; ChiCTR2000030054-HCQ (Chen), 2020 (ChiCTR2000030054) ; Gautret et al., 2020 ()

<sup>3</sup>Andreas (NOR-Solidarity), 2021 (NCT04321616) ; Norwegian NOR study (remdesivir), 2021 (NCT04321616)

<sup>4</sup>Jun C, 2020 (NCT04252274)

<sup>5</sup>Magagnoli (HC AZ), 2020 ()

<sup>6</sup>EPIC-SR, 0 (NCT05011513)

<sup>7</sup>ELACOI (Standard of care), 2020 (NCT04252885)